WHO Model Prescribing Information: Drugs Used in Parasitic Diseases - Second Edition
(1995; 152 pages) [French] [Spanish] View the PDF document
Table of Contents
View the documentPreface
Close this folderProtozoa
Close this folderAmoebiasis and giardiasis
View the documentMetronidazole
View the documentDiloxanide
View the documentDehydroemetine
View the documentChloroquine
View the documentBabesiosis
View the documentFree-living amoebae
Open this folder and view contentsLeishmaniasis
Open this folder and view contentsMalaria
View the documentMiscellaneous intestinal infection
Open this folder and view contentsPneumocystosis
Open this folder and view contentsToxoplasmosis
Open this folder and view contentsTrichomoniasis
Open this folder and view contentsAfrican trypanosomiasis
Open this folder and view contentsAmerican trypanosomiasis
Open this folder and view contentsHelminths
View the documentSelected WHO publications of related interest
View the documentBack cover


Group: luminal amoebicide
Tablet 500 mg of diloxanide furoate

General information

An amoebicide that is active only against organisms in the gastrointestinal contents. Less than 10% of an oral dose is excreted in the faeces, but sufficient amounts reach the colonic lumen to eradicate intraluminal forms of E. histolytica. The remainder is hydrolysed within the intestinal mucosa as it is absorbed and subsequently excreted in the urine as the glucuronide. Concentrations attained in tissues, including the intestinal mucosa, are subtherapeutic.

Clinical information



• treatment of asymptomatic carriers in non-endemic areas
• eradication of residual amoebae in the colonic lumen following treatment of invasive disease with antiamoebic drugs.

Dosage and administration

Adults: 500 mg three times daily for 10 days.

Children: 20 mg/kg daily in three divided doses for 10 days.

Treatment is regarded as successful if stools remain free of E. histolytica for one month. Several specimens should be examined in evaluating the response to treatment.

Contraindications and precautions

Diloxanide appears to be essentially nontoxic and is well suited to outpatient use.

Use in pregnancy

No untoward effects have been demonstrated but treatment is best deferred, when possible, until after the first trimester of pregnancy.

Adverse effects

Mild gastrointestinal symptoms, particularly flatulence, may be troublesome. Pruritus and urticaria can also occur.


Tablets should be kept in well-closed containers, protected from light.

to previous section
to next section
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: October 29, 2018